Home › Research › Prevention and risk
Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study
Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC et al.. Archives of general psychiatry, 2005-02-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Prior reports suggest reduced occurrence of dementia and Alzheimer disease (AD) in statin users, but, to our knowledge, no prospective studies relate statin use and dementia incidence. Objective To examine the association of statin use with both prevalence and incidence of dementia and AD. Design Cross-sectional studies of prevalence and incidence and a prospective study of incidence of dementia and AD among 5092 elderly residents (aged 65 years or older) of a single county. Participants were assessed at home in 1995-1997 and again in 1998-2000. A detailed visual inventory of medicines, including statins and other lipid-lowering agents, was collected at both assessments. Main outcome measures Diagnosis of dementia and of AD. Results From 4895 participants with data sufficient to determine cognitive status, we identified 355 cases of prevalent dementia (200 with AD) at initial assessment. Statin use was inversely associated with prevalence of dementia (adjusted odds ratio, 0.44; 95% confidence interval, 0.17-0.94). Three years later, we identified 185 cases of incident dementia (104 with AD) among 3308 survivors at risk. Statin use at baseline did not predict incidence of dementia or AD (adjusted hazard ratio for dementia, 1.19; 95% confidence interval, 0.53-2.34; adjusted hazard ratio for AD, 1.19; 95% confidence interval, 0.35-2.96), nor did statin use at follow-up (adjusted odds ratio for dementia, 1.04; 95% confidence interval, 0.56-1.81; adjusted odds ratio for AD, 0.85; 95% confidence interval, 0.32-1.88). Conclusions Although statin use might be less frequent in those with prevalent dementia, we found no association between statin use and subsequent onset of dementia or AD. Further research is warranted before costly dementia prevention trials with statins are undertaken.
What this study adds
Evidence grade: Low
This is a cross-sectional study of 4,895 participants. In this study, statin use was associated with lower prevalence of dementia at the initial assessment, but statin use at baseline did not predict who developed dementia or Alzheimer's disease three years later. The authors concluded there was no association between statin use and subsequent onset of dementia or Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zandi, P. P., Sparks, D. L., Khachaturian, A. S., Tschanz, J., Norton, M., Steinberg, M., et al. (2005). Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Archives of general psychiatry. https://doi.org/10.1001/archpsyc.62.2.217
Vancouver
Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Archives of general psychiatry. 2005. doi:10.1001/archpsyc.62.2.217. PMID: 15699299.
BibTeX
@article{zandi2005-15699299,
author = {Zandi, P. P. and Sparks, D. L. and Khachaturian, A. S. and Tschanz, J. and Norton, M. and Steinberg, M. and Welsh-Bohmer, K. A. and Breitner, J. C. and others},
title = {{Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study}},
journal = {Archives of general psychiatry},
year = {2005},
doi = {10.1001/archpsyc.62.2.217},
pmid = {15699299},
url = {https://doi.org/10.1001/archpsyc.62.2.217}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results From 4895 participants with data sufficient to determine cognitive status, we identified 355 cases of prevalent dementia (200 with AD) at initial assessment.
- Statin use was inversely associated with prevalence of dementia (adjusted odds ratio, 0.44; 95% confidence interval, 0.17-0.94).
- Conclusions Although statin use might be less frequent in those with prevalent dementia, we found no association between statin use and subsequent onset of dementia or AD.
Why it matters
In this study, statin use was associated with lower prevalence of dementia at the initial assessment, but statin use at baseline did not predict who developed dementia or Alzheimer's disease three years later. The authors concluded there was no association between statin use and subsequent onset of dementia or Alzheimer's disease.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designcross-sectional
- Participants4,895
- Evidence strengthLow
How this study scored 59/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Archives of general psychiatry) |
| Journal's citation record | 4 / 4 | Archives of General Psychiatry: journal h-index 543 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2005 — older than 20 years, still counted |
| Sample size | 3 / 4 | 4,895 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 310 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 13.5 citations a year over 23 year(s) since 2005 |
| Impact for its field and year | 5 / 6 | Cited 20.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 17 other studies in this library |
| Still being cited | 2 / 4 | Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Peter P. Zandi: h-index 92 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Johns Hopkins University: institution h-index 2,306 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 15699299) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
17 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Prevention and risk from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.